BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19663889)

  • 1. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.
    Trappe R; Hinrichs C; Appel U; Babel N; Reinke P; Neumayer HH; Budde K; Dreyling M; Dührsen U; Kliem V; Schüttrumpf S; Hauser IA; Mergenthaler HG; Schlattmann P; Anagnostopoulos I; Doerken B; Riess H
    Am J Transplant; 2009 Oct; 9(10):2331-7. PubMed ID: 19663889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
    Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
    J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
    Choquet S; Trappe R; Leblond V; Jäger U; Davi F; Oertel S
    Haematologica; 2007 Feb; 92(2):273-4. PubMed ID: 17296588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
    Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
    Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
    Trappe RU; Choquet S; Reinke P; Dreyling M; Mergenthaler HG; Jäger U; Kebelmann-Betzing C; Jonas S; Lehmkuhl H; Anagnostopoulos I; Leblond V; Hetzer R; Dörken B; Riess H; Oertel S
    Transplantation; 2007 Dec; 84(12):1708-12. PubMed ID: 18165786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
    Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
    Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
    Burns DM; Clesham K; Hodgson YA; Fredrick L; Haughton J; Lannon M; Hussein H; Shin JS; Hollows RJ; Robinson L; Byrne C; McNamara C; Vydianath B; Lennard AL; Fields P; Johnson R; Wright J; Fox CP; Cwynarski K; Chaganti S
    Transplantation; 2020 Dec; 104(12):2582-2590. PubMed ID: 33104308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B; Riella LV; Dierickx D
    Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of PTLD with rituximab or chemotherapy.
    Elstrom RL; Andreadis C; Aqui NA; Ahya VN; Bloom RD; Brozena SC; Olthoff KM; Schuster SJ; Nasta SD; Stadtmauer EA; Tsai DE
    Am J Transplant; 2006 Mar; 6(3):569-76. PubMed ID: 16468968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extreme hypercalcemia in a kidney transplant recipient.
    Demir E; Karaoglan C; Yegen G; Sair B; Yazici H; Turkmen A; Sever MS
    CEN Case Rep; 2018 Nov; 7(2):229-233. PubMed ID: 29705974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
    Kuriyama T; Kawano N; Yamashita K; Ueda A
    J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
    Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
    Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases.
    Patel H; Vogl DT; Aqui N; Shaked A; Olthoff K; Markmann J; Reddy R; Stadtmauer EA; Schuster S; Tsai DE
    Leuk Lymphoma; 2007 May; 48(5):885-91. PubMed ID: 17487731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
    Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.